In-process rAAV genome titer assays on QIAcuity—a fully integrated and scalable digital PCR platform
Time: 4:00 pm
day: Day One
As gene therapy programs grow in number and scale, manufacturing processes must keep pace with demand by providing the speed, throughput, and automation necessary for advancement. Droplet digital PCR is the current gold standard for quantifying rAAV genomes but suffers from a long turn-around time and low throughput. The QIAcuity dPCR system provides a fully integrated solution that reduces hands-on time while improving throughput and turn-around time.
A comparison of in-process samples to the current gold standard system shows that:
•QIAcuity dPCR is as accurate as the current gold standard but also at a lower cost and much higher throughput
•Sample preparation and upstream optimization are key for accurate in-process rAAV genome titer quantitation